NuVasive, Inc. (NASDAQ:NUVA) is reporting second quarter financial results on Tuesday 4th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, NUVA is expected to report 2Q20 loss of $ 0.47 per share from revenue of $ 175.79 million.
For the full year, analysts anticipate top line of $ 982.17 million, while looking forward to income of $ 0.90 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,215.00 million ~ $ 1,238.00 million, where as bottomline are predicted in a range of $ 2.55 ~ $ 2.65 per share
Click Here For More Historical Outlooks Of NuVasive, Inc.
Previous Quarter Performance
NuVasive, Inc. announced income for the first quarter of $ 0.48 per share, from the revenue of $ 259.88 million. The quarterly earnings dropped 9.43 percent while revenues shrunk 5.42 percent compared with the same quarter last year.
According to street consensus, NUVA was expected to report 1Q20 income of $ 0.43 per share from revenue of $ 273.88 million. The bottom line results beat street analysts by $ 0.05 or 11.63 percent, at the same time, top line results fell short of analysts by $ 14 million or 5.11 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of NuVasive, Inc.
Stock Performance
According to the previous trading day, closing price of NUVA was $ 55.74, representing a 95.24 % increase from the 52 week low of $ 28.55 and a 31.95 % decrease over the 52 week high of $ 81.91.
The company has a market capital of $ 2.86 billion and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”NUVA” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 23rd June 2020, upgraded by Needham & Company LLC to Buy from Hold rating.
Conference Call
NuVasive, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.nuvasive.com
NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The companys principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
